Effect of hydroxyurea on hemoglobin S;Efecto de la hidroxiurea en hemoglobina S

Medicina

Volumn 63, Issue 2, 2003, Pages 140-142

  Torres, Aurora Feliu ^a   Eandi Eberle, Silvia ^a   Sciuccati, Gabriela ^a   Bonduel, Mariana ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Hemoglobin S; Hydroxiurea

Indexed keywords

DEFEROXAMINE; FOLIC ACID; HEMOGLOBIN S; HYDROXYUREA; PENICILLIN G;

ARTICLE; BLOOD TRANSFUSION; BONE MARROW TOXICITY; CASE REPORT; CHILD; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; HEMATOLOGICAL PARAMETERS; HOSPITALIZATION; HUMAN; LIVER TOXICITY; LONG TERM CARE; MALE; NEPHROTOXICITY; QUALITY OF LIFE; SICKLE CELL ANEMIA; SICKLE CELL CRISIS;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; ARTERIAL OCCLUSIVE DISEASES; BLOOD TRANSFUSION; CHILD; HEMOGLOBIN, SICKLE; HUMANS; HYDROXYUREA; MALE;

EID: 0038279894     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 2002, 9: 101-6
2. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999; 340: 1021-31
3. Steinberg MH, Griffin PR. Pathophysiology of sickle cell disease: role of cellular and genetic modifiers. Semin Hematol 2001, 38: 299-306
4. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337: 762-9
5. Atweth GF and Loukopulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and β-thalassemia. Seminars in Hematology, 2001; 38: 367-73
6. Charache S, Terrin ML, Moore RD. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332: 1317-22
7. Bain BJ. Basic haematological techniques. In: Dacie JV, Lewis SM (eds). Practical Haematology. 9th ed. Edinburgh: Churchill Livingstone, 2001, p 27-30.
8. Brozovi'c M, Henthorn J. Investigation of abnormal haemoglobins and thalassaemia. In: Dacie JV, Lewis SM (eds). Practical Haematology. 9th ed. Edinburgh: Churchill Livingstone, 2001, p 231-267.
9. Chudwin, DS and Rucknagel, DL. Immunological quantification of hemoglobins F and A2. Clinical Chimica Acta 1974; 50: 413.
10. Kinney T, Helms RW, O'Branski E. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Blood 1999; 94: 1550-4
11. Koren A, Segal-Kupershmit D, Zalman L. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell β-thalassemia. Pediatric Hematology and Oncology 1999; 16: 221-32
12. Scott JP, Hillery CA, Brown ER. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 1996; 128: 820
13. Voskaridou E, Kalotychou V, Loukopoulos D. Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell / β thalassaemia. Br J Haematol, 1995; 89: 479-84
14. Ferster A, Tahriri P, Vermylen C. Five years of experience with hydroxyurea in children and young adults with sickle cell disease Blood 2001; 97: 3628-32.